Acrivon Therapeutics, Inc. Common Stock beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses), averaging +4.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.49 | $-0.43 | +12.2% | Beat | |
| Q1 FY26 | $-0.49 | $-0.49 | +0.0% | Beat | |
| Q4 FY25 | $-0.49 | $-0.49 | +0.0% | Beat |
Back to ACRV overview · ACRV holders · ACRV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.